[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-281408-105":53,"doc-detail-281408-en":127},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":120,"head_meta":122,"extra_data":124,"updated_unix":126},105,"en","policy-for-recall-of-drugs-and-healthcare-products","Policy for Recall of Drugs and Healthcare Products","","Policy for the recall of drugs and healthcare products issued by the Drugs and Medical Products Section at the Health Authority Abu Dhabi (HAAD). It standardises how deficient or suspected products are withdrawn and held from use or from the Abu Dhabi market pending HAAD investigation, including criteria for identifying deficiency and requirements for timely completion after recall issuance. It defines applicability to licensed healthcare facilities, professionals, market authorisation holders and relevant government entities, and sets out escalation, investigation, quarantine, and stakeholder compliance obligations, including possible sanctions.",{"@graph":63,"@context":119},[64,80,102],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":41,"@type":70,"position":76},"https://docshare.wps.com/template/letters/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/policy-for-recall-of-drugs-and-healthcare-products/281408/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/policy-for-recall-of-drugs-and-healthcare-products/281408.png","ImageObject",442,249,{"name":88,"@type":89},"Taylor Morgan","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-10-19","2026-09-16",true,{"@type":98,"interactionType":99,"userInteractionCount":101},"InteractionCounter",{"@type":100},"ViewAction",10,{"@type":103,"mainEntity":104},"FAQPage",[105,111,115],{"name":106,"@type":107,"acceptedAnswer":108},"What is the purpose of this recall policy?","Question",{"text":109,"@type":110},"It standardises the process for recalling drugs and healthcare products in Abu Dhabi, covering actions taken by healthcare facilities/market vendors and HAAD.","Answer",{"name":112,"@type":107,"acceptedAnswer":113},"How does HAAD define a deficient product?",{"text":114,"@type":110},"A deficient product is any product that does not meet required quality specifications or is contaminated, counterfeit, fake, mislabeled, or otherwise presents efficacy, quality, or safety issues that may harm patients.",{"name":116,"@type":107,"acceptedAnswer":117},"What are the timelines and requirements after HAAD investigation and recall issuance?",{"text":118,"@type":110},"For Class II and III recalls, the recall process must be completed within 3 weeks after issuance. For Class I (Critical) recalls, HAAD-declared recalls are effective immediately after issuance.","https://schema.org",{"og:url":78,"og:type":121,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":123,"canonical":78},"index,follow",{"doc_id":125,"site_id":56},281408,1790157932,{"code":4,"msg":5,"data":128},{"doc_id":125,"user_id":129,"nickname":88,"user_avatar":130,"doc_module":9,"category_id":40,"category_name":41,"doc_title":59,"doc_description":61,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":101,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":47,"language":136,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":137,"faqs":138,"seo_title":139,"seo_description":61,"update_tm":140,"read_time":73},1099523885336,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","| Health Authority – Abu Dhabi |  |  | |\n| --- | --- | --- | --- |\n| Document Title: | Policy for Recall of Drugs and Healthcare Products |  |  |\n| Document Ref.\u003Cbr>Number: | PPR/DMP/DR/P0001 | Version | 0.9 |\n| Approval Date: | August 2007 | Effective Date: | August 2007 |\n| Last Reviewed: | June 2012 | Next Review: | December 2013 |\n| Revision History | N / A |  |  |\n| Document Owner: | Drugs and Medical Products Regulation Section/Health Regulation Division |  |  |\n| Applies to: | Healthcare Facilities and Professionals Licensed by HAAD in the Emirate of Abu Dhabi |  |  |\n| Classification: | 􀂀 Public |  |  |\n\n1. PURPOSE  \nTo standardise the process of recall of drugs and healthcare products by the Drugs and Medical Products Section at the Health Authority Abu Dhabi (HAAD) from the healthcare facility/market/vendor in the Emirate of Abu Dhabi.  \n2. POLICY STATEMENT  \n2.1. Drugs and Medical Products Section at HAAD is responsible for issuing, ordering, reporting and monitoring drug/ medical products and healthcare product recallsin the Emirate of Abu Dhabi.  \n2.2. This policy encompasses all types of drugs and healthcare products, which have been identified or suspected to have deficiencies.  \n2.3. Drugs and healthcare products identified or suspected to have deficiencies must immediately be withdrawn and held from use by healthcare facilities or from the market in the Emirate of Abu Dhabi, until HAAD commissioned investigation is completed.  \n2.3.1. A Deficient product is any product that does not comply with quality specification (as per UAE adopted pharmacopeias or manufacturer’s approved specifications) or is contaminated, counterfeit, fake, mislabeled, and presents efficacy , quality or safety issue that may harm patients.  \n2.4. Once HAAD investigation of the suspected drug/ healthcare product is completed and recall is issued (Class II and III), compliance by all stakeholders is mandatory and the process of recall must be completed within 3 weeks after the issuance of the recall.  \n2.5. For Class I (Critical) , HAAD declared recalls will be effective immediately after the issuance of the recall (Appendix 1) .  \n2.6 All stakeholders must comply with this policy; non-compliance may result in sanctions and penalties being imposed by HAAD which may range from warnings, fines, other disciplinary actions, or to closure of facilities.  \n3. SCOPE  \nFor consumer protection, patient safety and quality of care, recalls are processed and issued for drugs and/or healthcare product which fail to comply with any article of UAE pharmacy law and is applicable at all levels of drugs and healthcare products  \nhandling, including supply chains, retail, healthcare facilities, pharmacies , and where deficiencies are identified during inspections, post marketing surveillance and/or through customer complaints.  \n4. TARGET AUDIENCE  \n4.1. Healthcare professionals and healthcare facilities licensed by HAAD in the Emirate of Abu Dhabi  \n4.2. Market authorisations holders  \n4.3. Abu Dhabi and Federal Government entities , in particular the Ministry of Health (MOH)  \n5. PROCEDURE  \n5.1. Healthcare facilities must inform HAAD immediately as they become aware of information that indicates or suggests that a drug or medical product is deficient or is suspected of being deficient;  \n5.2. All healthcare professionals working in healthcare facilities must first inform the head of their pharmacy department about any suspected product. Deficient and suspected products must be put on hold and not be used or recommended for use until HAAD investigates and issues final decision about the concerned product.  \n5.3. Healthcare facilities must report information on the deficient or suspected drugs or medical products by completing the reporting form (Appendix 2) and faxing/sending it to HAAD. Reports may also be submitted via mail, e-mail and telephone. HAAD recommends that report originators must ensure that the information was received by Drugs and Medical Pr","cbCaikwUsovEpyKV","https://ap.wps.com/l/cbCaikwUsovEpyKV","pdf",168163,"English","# PURPOSE\n# POLICY STATEMENT\n## Types and classification of recalls\n# SCOPE\n# TARGET AUDIENCE\n# PROCEDURE\n## Notification and reporting\n## HAAD investigation and actions\n## Responsibilities of market authorisation holders","[{\"question\":\"What is the purpose of this recall policy?\",\"answer\":\"It standardises the process for recalling drugs and healthcare products in Abu Dhabi, covering actions taken by healthcare facilities/market vendors and HAAD.\"},{\"question\":\"How does HAAD define a deficient product?\",\"answer\":\"A deficient product is any product that does not meet required quality specifications or is contaminated, counterfeit, fake, mislabeled, or otherwise presents efficacy, quality, or safety issues that may harm patients.\"},{\"question\":\"What are the timelines and requirements after HAAD investigation and recall issuance?\",\"answer\":\"For Class II and III recalls, the recall process must be completed within 3 weeks after issuance. For Class I (Critical) recalls, HAAD-declared recalls are effective immediately after issuance.\"}]","Policy for Recall of Drugs and Healthcare Products | PDF",1789566012]